Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 7/20 | 0.38 |
| ▸ | CTSS | P25774 | 7/20 | 0.38 |
| ▸ | CTSK | P43235 | 7/20 | 0.38 |
| ▸ | CTSB | P07858 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CCR6 | P51684 | 1/20 | 0.36 |
| ▸ | CTSV | O60911 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6832344 | 0.89 | CTSK (0.37) | CTSLCTSSCTSKCTSBALDH1A1 | |
| SCHEMBL4317769 | 0.85 | CTSK (0.42) | CTSLCTSSCTSKCTSBCTSV | |
| SCHEMBL4323929 | 0.85 | CTSK (0.42) | CTSLCTSSCTSKCTSBCTSV | |
| SCHEMBL4323933 | 0.85 | CTSK (0.42) | CTSLCTSSCTSKCTSBCTSV | |
| SCHEMBL6838419 | 0.82 | CTSK (0.52) | CTSLCTSSCTSKCTSBCTSV | |
| SCHEMBL6836232 | 0.82 | CTSK (0.52) | CTSLCTSSCTSKCTSBCTSV | |
| SCHEMBL6838157 | 0.82 | CTSK (0.52) | CTSLCTSSCTSKCTSBCTSV | |
| SCHEMBL5099022 | 0.81 | CTSK (0.53) | CTSLCTSSCTSKCTSBCTSV | |
| SCHEMBL6835425 | 0.80 | ALOX5AP (0.36) | CTSLCTSSCTSKALDH1A1KDM4E | |
| SCHEMBL5096645 | 0.77 | CTSK (0.37) | CTSLCTSSCTSKCTSBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038965-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038965-A1 | Protease inhibitors | CTSK, CTSZ, CTSE | CTSL 14/4885CTSS 6/4885CTSK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.